Skip to main content
. Author manuscript; available in PMC: 2012 Jun 26.
Published in final edited form as: Mol Cancer Ther. 2009 May 5;8(5):1340–1349. doi: 10.1158/1535-7163.MCT-08-1136

Table 2.

Comparative killing ability of TG versus its analogues against a series of human prostate cancer cell lines

Cell line Killing ability of compound

(LD50 nmol/L)*

TG 12ADT A12ADT L12ADT D12ADT
LNCaP 10 ± 5 55 ± 12   8 ± 4 14 ± 8 40 ± 12
LAPC-4 25 ± 6 80 ± 19 28 ± 7 32 ± 9 55 ± 9
VCaP 20 ± 7 67 ± 25 23 ± 9 25 ± 11 70 ± 18
MDA-PC-2b 43 ± 12 95 ± 35 40 ± 6 42 ± 5 51 ± 12
CWR22Rv1 38 ± 9 85 ± 27 38 ± 11 34 ± 16 39 ± 7
*

Values are the mean of a minimum of three independent experiments ± SE.